Featured Research

from universities, journals, and other organizations

Understanding A Target Of Quinoline Drugs

Date:
April 27, 2009
Source:
Public Library of Science
Summary:
The full details about the molecules and mechanisms that underlie the development of autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, remain to be discovered. One compound that may have a role in alleviating these conditions is quinoline-3-carboxamide. Researchers have now identified a molecular target for quinoline compounds.

The full details about the molecules and mechanisms that underlie the development of autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, remain to be discovered.

Related Articles


One compound that may have a role in alleviating these conditions is quinoline-3-carboxamide, which is currently being tested in various clinical trials. In this week's PLoS Biology, researchers from Lund University, Sweden, the University of Munster in Germany, and the company Active Biotech AB, identify a molecular target for quinoline compounds.

This study shows that quinoline compounds bind to a molecule called S100A9, which is expressed in some white blood cells that are involved in the regulation of immune responses. Furthermore, S100A9 interacts with two known pro-inflammatory receptors (Toll like receptor 4 (TLR4) and receptor of advanced glycation end products (RAGE), and this interaction is inhibited by quinoline compounds.

The published data describe a new mechanism whereby S100A9 can promote pro-inflammation at early stages of immune activation. These findings may lead to an increased understanding of the early steps in the development of autoimmune disease.

Three of Active Biotech's projects (laquinimod, 57-57 and TASQ) belong to the quinoline chemical class of compounds.

The Swedish Cancer Society, The Swedish Research Council, Kocks Foundation, Φsterlund Foundation and German Research Foundation funded this work. The funders had no role in study design, data collection, decision to publish, or preparation of the manuscript.

Some of the other authors have full time employment status at Active Biotech and 1 author has a research grant from Active biotech (for another project).


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bjφrk et al. Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides. PLoS Biology, 2009; 7 (4): e97 DOI: 10.1371/journal.pbio.1000097

Cite This Page:

Public Library of Science. "Understanding A Target Of Quinoline Drugs." ScienceDaily. ScienceDaily, 27 April 2009. <www.sciencedaily.com/releases/2009/04/090427203659.htm>.
Public Library of Science. (2009, April 27). Understanding A Target Of Quinoline Drugs. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2009/04/090427203659.htm
Public Library of Science. "Understanding A Target Of Quinoline Drugs." ScienceDaily. www.sciencedaily.com/releases/2009/04/090427203659.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins